All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The GvHD Hub is an independent medical education platform, sponsored by Medac and supported through grants from Sanofi and Therakos. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Bookmark this article
During the 63rd ASH Annual Meeting and Exposition, the GvHD Hub was pleased to speak to Shernan Holtan, University of Minnesota, Minneapolis, US. We asked, How could urinary-derived human chorionic gonadotropin (uhCG)/epidermal growth factor (EGF) fit into current acute GvHD treatment pathways?
How could uhCG/EGF fit into current aGvHD treatment pathways?
Holtan discusses the use of uhCG/EGF in the frontline high-risk setting. Holtan also discusses the administration and monitoring of uhCG/EGF in patients with GvHD.
Subscribe to get the best content related to GvHD delivered to your inbox